Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 6/20 | 0.37 |
| ▸ | CDK2 | P24941 | 6/20 | 0.37 |
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24741966 | 1.00 | CCNE1 (0.37) | CCNE1CDK2GSK3BCYP3A4GAA | |
| SCHEMBL31028793 | 1.00 | CCNE1 (0.37) | CCNE1CDK2GSK3BCYP3A4GAA | |
| SCHEMBL22312645 | 0.86 | CCNE1 (0.35) | CCNE1CDK2GSK3BCYP3A4GAA | |
| SCHEMBL29987604 | 0.82 | CCNE1 (0.39) | CCNE1CDK2GSK3BCYP3A4GAA | |
| SCHEMBL17387673 | 0.79 | CYP3A4 (0.43) | CYP3A4GAACYP2C19TGFBR1 | |
| SCHEMBL2419398 | 0.79 | CYP3A4 (0.43) | CYP3A4GAACYP2C19TGFBR1 | |
| SCHEMBL25345989 | 0.79 | — | — | |
| SCHEMBL25348163 | 0.79 | — | — | |
| SCHEMBL31059664 | 0.79 | — | — | |
| SCHEMBL25348190 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587438-A1 | BICYCLIC COMPOUNDS AS CDK INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025136671-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-119894890-A | Bicyclic compounds as CDK inhibitors | 百济神州(苏州)生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4540230-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119384413-A | Anilino-pyrazole derivatives, compositions and methods thereof | 昂胜医药有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | GENENTECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240317777-A1 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240294506-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024178335-A2 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| EP-4412995-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | Genentech, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-115806551-A | Pyrazole-containing polycyclic derivative, pharmaceutically acceptable salt thereof, and preparation method and application thereof | 优领医药科技(香港)有限公司 | 2023-03-17 | — | — | CN | disclosed |
| WO-2022206888-A1 | CDK2 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022018596-A1 | COMBINATION THERAPY | PFIZER INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022018667-A1 | COMBINATION THERAPIES USING CDK2 AND CDC25A INHIBITORS | PFIZER INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-3917913-A2 | 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS HAVING INHIBITORY ACTIVITY ON CDK2 | Pfizer Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11014911-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014911-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200247784-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200247784-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2020157652-A2 | CDK2 INHIBITORS | PFIZER INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | CDK2, CCNI, CDK20 | CCNE1 26/4885CDK2 1/4885GSK3B 182/4885 |
| US-20200247784-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | CCNE1 8/4885CDK2 1/4885GSK3B 114/4885 |
| US-20240294506-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | CCNE1 8/4885CDK2 1/4885GSK3B 114/4885 |
| US-20240317777-A1 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK20, CDK3 | CCNE1 43/4885CDK2 1/4885GSK3B 117/4885 |
| US-11014911-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | CCNE1 8/4885CDK2 1/4885GSK3B 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.